AbbVie Inc. closed at $226.22 on October 15, 2025, down 1.27% from the previous session, continuing a modest decline over the past week despite strong business momentum. The company recently reported robust second-quarter results, with worldwide net revenues rising 6.6% and significant growth in its immunology portfolio, notably Skyrizi and Rinvoq. AbbVie also raised its full-year 2025 adjusted EPS guidance to $11.88–$12.08, reflecting confidence in its diversified growth platform and pipeline progress. The recent price movement likely reflects profit-taking and cautious sentiment as investors weigh the impact of these positive fundamentals against broader market uncertainty and the sharp drop in Humira revenues. No new major company-specific news was reported on October 15, 2025, but the Q2 earnings and guidance update remain the dominant drivers for ABBV's current valuation.